Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions

17 Mar 2021

Abstract excerpt

gene therapy approved in the US and Europe. The recent tragic death of three children in a clinical trial to treat X-Linked Myotubular Myopathy by delivering myotubularin with an AAV8 vector notwithstanding, AAV remains a highly promising therapeutic gene delivery platform. But the successful use of AAV vectors to treat an increasing number of diseases also makes establishing protocols to determine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infections and Immunology Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33815421
DOI: 10.3389/fimmu.2021.658399

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible SolutionsPMID 33815421Read ↗

Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.Semantic proximity Read ↗

Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapySemantic proximity Read ↗

Evading and overcoming AAV neutralization in gene therapySemantic proximity Read ↗

Seroprevalence of binding and neutralizing antibodies against 18 adeno-associated virus types in patients with neuromuscular disordersSemantic proximity Read ↗

Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human TrialsSemantic proximity Read ↗

Recent Advancements in AAV-Vectored Immunoprophylaxis in the Nonhuman Primate ModelSemantic proximity Read ↗

Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular DystrophySemantic proximity Read ↗

Understanding AAV vector immunogenicity: from particle to patientSemantic proximity Read ↗

Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirementsSemantic proximity Read ↗

Humoral immune responses to AAV gene therapy in the ocular compartmentSemantic proximity Read ↗

Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerationsSemantic proximity Read ↗

Immune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical StudiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.